Ardian: Succeeding Where Drugs Fail--Treating Hypertension in the Cath Lab

Using the first catheter therapy for the interventional treatment of hypertension, this start-up's technology may be able to reduce blood pressure where drugs have not worked, and holds future promise for heart failure and kidney disease.

Large market opportunities have always been high on the checklists of investors, both venture and strategic, in evaluating prospective investments in device start-up companies. And with the constraints of the current financing climate, big market opportunities become an even more important criterion for emerging companies in order to satisfy investors' reduced appetites for risk.

There is often a disparity, however, between a start-up's assessment of a particular market's size and a venture capitalist's view of the same market

More from Global Vision

More from In Vivo